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ABSTRACT 
,_ 
This is an explorato·ry study of innovative organ-
i.zational structures and economic evaluation practices .and 
procedures for New Product Development,in Pharmaceutical 
Industry. While some guidelines have been laid out and 
some advanced methods of business analysis have been deve-
loped for New Product Introductions, catering to the needs 
of other consumer oriented industries; literatu~e on New 
Product Management remains rather obscure. Here, a first 
eyer attempt is made to establish the state of the art of 
introducing New Products (Organizational characteristics, 
·-
·use of advanced business management techniques, problems 
of New Product~Introductions, etc.) within the Phatmaceu-
tical Industry, and to determine the extent to which the 
knowledge available to and/or applied by other consumer 
\ 
oriented industries is also utilized by the Pharmaceutical 
Manufacturers. Finally·, the study identifies the reasons 
/ contributing most towards the discontinuance of New Pro-
duct proposals in this industry. The results and conclu!'! ___ .,._ .. 
sions presented here are based on the information received 
in an inq.ust-rial survey, in which the information was 
requested of all 103 national Pharmaceutical Companies. 
The information presented and the conclusions drawn there· 
\(., .. ,,-·•"'''' 
from should Qe of help and.interest to the Pharmaceutical 
Manufacturers. 
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CHAPTER I .•. 
INTRODUCTION 
With the growth of American Economy, new product 
d.evelopment has become a factor of prime importance. Even 
· two decades back formal organizational str~cture and plan-
ning and control procedures,·to analyze this management 
function were largely unknown. Today, new product develop-
ment is estimated to be"a $ 12 billion to$ 15 billion a 
year activity. Orte might wonder after all what is it that 
. . 
makes new product development so important! The answer lies 
in the fact that the present day American economy is an 
• 
economy of plenty, which has largely met the demands of 
basic physical needs. As a result markets have expanded and 
. (17) ~ 
severe competetion among manufacturers existso Under the 
circumstances most companies have to adopt a new product 
. ' 
development function to ensure their survival. In this cpn-(16) · · . 
text, Kotler says,"Under modern conditions of competition, 
- . 
it is becoming increasingly risky not to innovate. Consumer 
and industrial ctistome~ want and expect a stream of new and 
improved products. Competition would certainly do its best 
to meet these desires. Continious innovation seems to be 
the way to avert obsolescence of the company's product line." 
So we see, that new product development is a matter of surv-
ival, an insurance against being wiped out by competition 
- 1 -
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and an investment in the future. And to make·things worse, 
' 
• new product development is a very difficult task. In fact, 
·recent studies have .shown that new product failure now runs· ·. _ . 
............... , .... · · ··········· · ·as high· as ao·%· and the waste· in· research has been estimated 
. _ (30) 
~-
at 70%or more. T~e loss of money is of far less conseqtience 
than misdirection and waste of technical and marketing man-
power. 
Irt view of the above, it can be safely said that 
what is required, is more attention to new product develop-
ment function (i.e., better statement of company policy and 
a good innovative organization), and availability of good 
new product planning and control techniques • 
• 
, 
Corporate Policy on New Products1 
Once a company has decided to engage in new pro-
duct development activity, the corpora~e goals in this con-
text should be clearly defined. The company objectives, in 
general would include some combination o:f the following 
three goals, to protect pr~sent earnings and position;· to 
reach beyond competition to improve the company's positin 
in its present field and to enter new fields and achieve a (20) 
broader baseo But this statement of company objectives is 
. (24) very conceptual and needs better. explanation, Rives suggests 
that ini tial~y the company should st·art by defining the new 
product ( to· differentiate from 'Product Modifi.cation •), the 
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, . contribution new products should make towards shipment and 
profits, the group assigned with new product development 
r responsibility and the frequency and method of control for 
new,product development, Later, some more intensive rese-
arch sh6uld be carried out to more objectively define com-
pany's new product policy. He continues, by stating that,a 
detailed statement of new product policy should include the 
following ten stepsa . -~. 
"1, Prepare a long range industry fore-
cast of existing product lines. 
2. Prepare a long range profit plan for the company using existing product lines. 
J. Reyiew the long range profit plan. 
4. Determine what role new products will play in the company's future. 
5. Prepare an invento~y of company cap-abililities. 
6. Determine market areas for new pro-ductso 
.. 
7. Prepare a statement of new company 
obj~ctives. 
8. Prepare a long range profit plan, in-corporating new pr.oducts. 
.. 
----:-. ' . -·-:---' _. ·___:.c; 
9. Assign.new product responsibilitj. 
10. Provide for evaluation of new pro-duct performance." 
By clearly defining the above ten :factors _of new product 
policy, the-.task of new product development is given a sys-
.. 
· tematic start. In fact, it is very important for the company 
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., to include new product development in -its long range plans, -
assign a -budget to new product development function and hold 
the new product devel<?pment group responsible for carrying 
t,. 
out their activities in conformance with the company•s·long (12) (24) 
range plans_. The findings of Hass and Rives seems to sub-
stantiate :that in most companies the policy matter regarding 
new product development function is largely undefined and 
... few companies include new product development in their~ong 
range planning •. 
Innovative Organization, 
The organization of_the"innovative group seems· to 
have receieved less attention in the new product developm·ent. 
literature than it is worthy of. Many people fail to realize 
the impact a properly organized innovative group can make on 
the mortality figures of new product developments. New pro-
duct development is a unique function, it require~ .. excep-. 
tional talents from the manager of this group itself. The 
manag~r of such a group should be a rare person combining 
the qualities of an organizer, analyst, gambler, inventor, 
dreamer, scientist and a leader. Because, what is required 
of his group is creativity and successful and meaningful 
output underrisk conditions 0 not to mention the fact that 
, 
comp~tition is trying to do the same with advanced techno-. 
. 
logy. In short, what is required of su,ch a group is that it 
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watch the market keenly, shorten the cycle of new product 
development., have fast reflex action, be prepared for great-
er risks in order to make the new product development a per-
petual process, whereby ideas are checked, rejected and 
.·· (30) 
worked upon continuallys Yet, the irony of the situation is 
that this organization of the innovative group has been and 
probabily still is the most negelected aspects of new pro-
_duct development in industry. Speaking of the impact a pro-
.. ( 10) . 
perly organized innova~ive group can make, Grayson reports 
' on the basis of his findings in packaging industry "that, 
"Companies organized with full time new product executives 
. 
~ 
produce 69.0% more new products than companies with part 
time executives, and 60.5% more than companies without any 
new product executives." 
Various types of new product organizations exist 
·in practice. Here, we woul~ define some of the popular ones. 
The ·first type is where the new product development function 
is adopted within the regular framework. Here, the vice.pre-
sident of marketing has the responsibility for new product 
development as 'well as for marketing, market planning,.mar-
ket research, sales advertising and promotion. In such an 
organization the product manager for existing product brands 
,• 
also serves as manager for ne~ product. developments It is 
doubted that such an organization would deliver an abundance 
of new products. Under the given environment one would ex-
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pect to find the .. product manager preoccupied with e.~isting 
brand products, 
• • The second type of organizational structure is 
one in which the responsibility for the new product dev.elop-
ment function is separated from the product manager for ex-
isting brands and is delegated· to a new products manager. 
Both the product managers for existing brands as well as 
for the new products are answerable to· -t-he vice president 
of marketing. 
In the third type of organizational str~cture, 
the new products development function is carried out by an 
• • • 
• 
· ad-hoc committee formed by representatives of marketing, 
research and development, production engineering, financ~, 
etc., reporting to the president. The committee meetings 
are called at regular intervals. Usually such an ad-hoc 
committee has no fund allocations of its own and is restric-
ted in its scope to a decision making committee functioning 
on democ.ratic principles. Under ·such an arrangement, the 
implementation aspects invariabily are the responsibility of 
some other group. Since the members of the committee (1) 
have new products development as a secondary function,.:· 
(2) have no individual responsibility (other than collective 
, responsibility as a committee· member) for the success and 
failure of the .P~ogram, and (3) have to ,elect proposals • 
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through elective procedures (with chances of lack of under-
standing by some committee members), this organizational 
structure may be instrumental in rejecting some good pro-
posals, while electing some not so good pro.posals. 
In the fourth type of organizational structure, 
the responsibilty for new products development function is 
contained within the confines of the research and develop-
ment department or is placed in close proximity there of. 
In such cases, usually the new products development group 
is only supposed to screen and evaluate the new products 
,. proposals, from there on the marketing people take over. 
Under such a system a zealous·research and development 
• 
department may develop an abundance of new product proposals 
that may ultimately fail in commercialization. Technical 
personnel in charge of the group may fail to ·realize the 
risks and .uncertainities involved • 
• 
·•! j The fifth type of new product organization i·s the 
one where an independent new products development group 
exists. This group directly reports to the president. Such 
a group staffs experts from several professions and has a 
_budget alloted to it. The group is allowed to·do its own 
screening, ··evaluation, technical research and ~evelopment, 
" 
marketing research, testing and initial commercialization. 
In short, such a group is responsible-for developing a new 
- ? -
0 
. ·-:-\' 
•. 
~;. ~:.,·•-
:, 
" 
,-.- __._, ·~· 
' product proposal. from a concept on· paper to a final product 
in market_ place. 
The last type of new products organizatio·nal stru-
, 
cture consists of venture teams (or task forces). Such a 
' team is constituted of professionals removed fromi their 
.. 
parent organizations for the duration of the project. The 
members of the team report to the new products development 
manager during their stay with the team. Here, the venture 
teams have an advantage over the ad-hoc committees in that 
these venture teams are not dispersed for members to return 
, .. 
to their parent organizations, after each meeting. Suell . 
teams are unique in certain ways. They have a membership of 
• 
the professionals from several diciplines gathered togather 
on a broad mission, where they can persue the goals of the 
team in their own manner, As there are no time dead lines 
to be met an ideal creative atmosphere exists. Since no 
formal heirarchy is defined (except for a group leader), and 
promotions are still dealt within the framework of parent 
organizations of .these specialists, the careerism competi-
tion is removed from this organization and a cordial person-
. ' 
al relationship and relaxed creative atmosphere:~·flo.ur'ishes. 
As, such teams are alloted their own funds and ·r-eport di- . 
rectly ~t the top, their work is considerabily facilitated. 
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Busine~s Analysis• 
Once a new product proposal has b~en screened and 
found to be worthy of possible development, a business 
. 
analysis regarding its profit making potential is made. 
-He~ej the new product development group makes certain mar-
keting estimates. The marketing criteria that may be i~-
" 
vestigated here can be Expented Price, Expected Volume, 
Expected Market Growth, Investment Requirements, Marketing 
and Promotionai Cos·ts, effect of new product on existing 
. product line~, Probability of Technical Success, etc • 
.. As none of these parameters can be estimated with a high 
degree of accuracy, especially·a year or two before com-
mercialization commences, the genralizations and estimates 
of product success at times are far from perfect. Another 
factor that contributes to the confusion and poor decision 
making is that until recently not very many good models 
were available that could take the uncertainities involved 
into consideration and serve as good tools of decision 
" 
making. In this context, in a recent study conducted to 
explore systematically the relation between estimated 
and actual outcomes in commercial development projects, 
_ ...... . 
--~·-···-··· o-- . 
from the data of five companies 
others) as· technical leaders in 
concludes a 
- .:. .. 
- 9 .:.·· 
.i 
that are considered· (by 
. ( 18) 
their fields Meadows 
' 
···-....... 
- ----~ --- <-" -d 
,..' 
., 
. .,~ 
,· 
----
~: 
.•r, 
- ;. . 
. ····-
"1. Current labo~atory procedures typi-
cally expend more than 50% of the firms,, 
development resources on projects that 
·do not produce commercially successful 
products." 
"2. There is a pronounced tendency for 
techni-cally and commercially unsuccess-
ful projects as a group to incur great-
er cost overruns than commercially suc-
cessful projectso When projects are ~ 
grouped according to their outcomes, 
the ratio of total actual costs to total 
estimated costs for the unsuccessful ~ 
projects of each laboratory is found to 
be greater than for the corresponding 
group of successful projects. 
J. Technically and commercially unsuc-
cessful projects cost more on the aver-
age than commercially successful pro-jects. y 
4. There is a low correlation between 
• the actual and estimated values of cost, 
_probability of technical success Q and 
probability of commercial success fig-
ures employed in selecting among pro-jectSrt99 
, 
In view of the above, it is not difficult to note that real-
istic estimates are difficult to make, and that the good 
business analysis methods are needed to help us make good 
decisions on the basis of these estimates, by taking the 
' inherent uncertainities into account. 
Let us examine some of· the techniques found in 
~ 
11·terature on new product business analysis. Various methods 
are available for this purpose. ·Some use simple math~matical. 
relations, others use complex computer simulation routines. 
Bayesiari statistics, decision theory, utility theory and 
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and their-applications have been used for this purpose. 
Recently a few specialized computer simulation routines 
such as 'DEMON~, 'SPRINTER', etc., have also emerged. 
One of these methods employed for summing up the 
research findings of various marketing criteria .. (mentioned 
earlier), in one decision factor is a simple mathematical 
relationship. The decision criteria determined by this re-
lationship has been called by various- names in literature 
depending upon which version of this rel~tionship is being ( 18 , 19 , 21 , 2 2 ·)· . 
used. The various terminologies used for it are Value Factor 
_of the New Product, Priority Number, Expected ~rofit Ratio, 
and Payback Index. What the formula really generates is a 
• 
ratio of expected profit of the new product (taking into 
consideration its probability of technical success and com-
mercial success) to the total expected investment required. 
The method pr.esented here has :found a wide application in 
industry, because of its simplicity; in spite of its·lim-
itations. The inherent danger in the method lies in the 
fact that the decision criteria is a expected value function 
and totally excludes any consideration of uncertainities 
involved. 
{11) 
Green suggests a decision tree type approach using 
Bayesian Decision Theory. In tnis approach, on the bassis 
·of estimates of various marketing criteria, the·process of 
- 11 -
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. new products planning and control is visualized as a deci-
sion tree of various options. Once the nature of these ·_; 
options has been determined and dollar value estimated, a 
posterior probability is assigned to each option. The deci-
sion tree is then solved for maximum expected profit, The 
path through the decision tree that optimizes the profit 
is used as a criterion for future action. No doubt, this 
approach has a large intutive appeal, but this approach 
also .suffers from the shortcoming that ultimately it also· 
uses an expected value criterion for decision making, The 
estimation of posterior probabilities may also be questioried.. 
(9) One other approach presented py Gottlieb and Rosh-
walb, is called 'Present Value Method_. by its proponents. · 
"This consists of discounting, by the firm1s marginal cost 
of capital, the incremental cash benefits expected over the 
life time of the project minus the incremental caah expend-
itures resulting from it", to yield expected return of an 
investment expe~iture is then used as a decision criterion, 
Since the basic model does not incorporate the use .of un-
certainities involved, a procedure for describing the degree 
of uncertainity about the possible outcomes (payoff) of a 
project by means of a probability distribution is examined, 
This procedure for including the uncertainity information 
consists in directing the questions about the uncertaini ty 
of possible outcomes (payoffs) of a project to the decision 
- 12 -
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maker and thereby. ascertaining.the probability distribution 
·parameters.A utility comparision approach is used to·decide 
between two or more projects. This model also has more or 
less the same shortcomings as the once mentioned henceforth. 
( 15) Yet another method is presented by Kotler, for 
business ana,lysis of new product development proposals. 
Here, the author attempts to find out the optimum market 
mix for new product proposal, _,and if the the project is 
worth ·while from an ecnomic st_andpoint. In th.is algorithum, 
the price range, total investment and overhead to be shared 
by the innovation per year are estimated. The break even· 
volume is then judged.at various prices in· the range esti-
mated for the price, with changing marketing mix alloca-
tions. For each price and marketing strategy the sales 
volume is estimated. Then from the estimated sales volume 
and break even point, for each marketing strategy the profit 
volume can be estimated. These .profits would be in the form 
of probability distribution, if the estimated sales volume 
for each marke-ting strategy was estimated ~s a probability 
,• distributiono The management can make its own expected 
I 
profit, uncertaini ty trade off either by plotting ind_iffer-
ence curves for various strategies or by making use ·of 
utility theory, to maximize the .expected utility of various 
marketing mixes. The rate of return orl. investment for each 
marketing mix can also be calculated, if the company wants 
- 13 -
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to consider only those possibilities where a certain rate 
of return is guarnteed, This is a very good approach .. On 
one hand the technique involved is simple, on the other·~~·- · 
hand the uncertaint~ data are properly utilized, As it 
considers various alternatives, the method can be a good 
guide for new product development group, to check the 
accuracy of their estimates and to help make better 
I 
decisions in future • 
(13) 
Hertz suggests in a method he pr_oposes, the use·· 
.. 
of a computer si~ulation routine to estimate the probabi-
lity distribution of rate of return from the input esti-
mates of various marketing criteria. According to him, the 
• 
estimates of market size, selling price, market growth 
rate, share of market, investment needed, residual value 
of investment, operating costs, fixed costs, useful life 
of facilities should be made as probability distributions. 
Then with the help of a computer simulation routine the 
probability of rate of return should be estimated. This 
probability distribution, he s~gests, should be used as a 
criterion for decision making. This approach seems to be 
more practical than others and results obtained should 
(23) 
have higher credence. Ransom mentions the use of this 
approach in E. I. DuPont De Nemours & Co. 
· - 14 -
,. ', . 
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Advanced Methods of New Product Introduction's 
In recent years, a_number of marketing research 
models have been developed, whereby it is possible to 
monitor a new product before during and after launching. 
The basic idea in all these models is that management 
states its policy constraints, on the basis of which the 
·~ new product is guided through preintroduction, introduc-
'·" tion and post introduction phases. In some of these meth-
ods, it is possible to actually tell the management the 
optimum marketing_ strategy for advertising, distribution, 
,, 
pricing,, etc. In othersr tne management can only detect 
when they are off the course and fro~ there on its upto 
I 
the management to decide what corrective measures should 
they take and ~ow much. Here, we present four such tech-
niques, namely 
1. Trajectory Theory of Goal Setting for New 
Products. 
. 
2. Program Eva.luation and Review Technique or 
Critical Path Method. 
3. Decision· Mapping via Optimum G'o-No Networks 
·I. Speeification of Profits with Interaction 
under Trial and Error Response. 
These are by no means the only. techniques i-n t.his ,field, 
-there are some lesser known techniques available in the 
literature. Even among the ones mentioned here only the 
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l~st two have gained popularity in literature, on new pro-
duct planning and control, especially the last one. 
( 7) 
Trajectory Theory of Goal Setting for New Products1 
Here the author draws an analogy between the 
firing of a guided missle and launching of a new product. 
According to him, in the firing of a guided missle 0 the 
trajectory is plotted in advance along the variations of 
direction, speed, heat, recording, etc., and again all 
these are measured periodically after firing, whereby· 
corrective measures can be taken in due time to still make 
the missle hit the target. Likewise, ·in launching of a new 
• product the management should state its objectives (target) 
in advance, the trajectory of the sales and other vari-
ables should then be drawn. Later in the early introduction 
phase, the product could then be monitiored on the basis 
of these trajectories, and remadial action could be taken 
as and when necessary. The method consists of taking follo-
wing steps, 
. 1. Selecting Variables 
2. Selecting the Research ·Technique.s 
J. Compiling the past data. 
4. Setting Trajectory Parameters. 
Author suggests, that we sho~ld st~t by selecting the 
variables to· be used·for controling th8 product introduc-
\ 
~-· 
.. ' ' 
.. 
-~· 
' 
~f.,, . 
.. 
tion later. Such variables would vary according to the 
charachterstics of the new product. The variables selected 
should be meaningful, measureable, actionable and graph-
able. After the selection of variables, the research ~tech-
niques that would be used for measurement of these vari-
ables are decided 0 on the basis of their suitability. Then 
the data is compiled on some Of the past products for re-
viewing the trajectory form. From the study of the past 
I 
' ' 
data and company,' s ·objectives, the parameters for ne\\' pro~ 
duct trajectories can easily be found. The author uses a 
fourth order polynomial for trajectory approximation. These ... 
. trajectories are then used for monitoring the launching of· 
• 
new product in introduction and post-introduction phases. 
The author reports the use of the technique in medical 
marketing research and gives a case history. The problems 
of gathering relevant back data, limitation of researcch 
techniques, setting up confidence limits, establishing 
confidence in the method and securing the necessary thro-
. . 
ugh planning are realized by the authors But the author 
feels that the technique has a.lot of promise and can be 
, very helpful, however, successful use of such a technique 
requires some basic e~irical rese~ch in the problem area, 
Program Evalua~ion and Review Technique/Critical Path 
Methods __ 
New Product Planning and Control through PERT~ 
- 17 -
. "''"' 
' ' 
.. 
-"· 
.. 
. ;··">· .. 
·-
,. 
I , 
. .,;,· .. , -· 
........... 
./ 
CPM or CPA type techniques has been suggested by a··rew 
model bui1ders and others interested in product management._ 
In all such models, the project is defined by elobrate new 
product introduction network of events ( tasks) that must (2,8,29) 
be accornp1ished. The network displays the interdependence 
of many events and activities necessary to new product 
introduction. Such models encourage and make it possible 
for the management to coordinate and control its new pro-
duct programs in a systematic fashion, The solution of the 
model _supplies the management with the information regard-
ing the activities which will b·e critical from time stand-
· point and 
corpo·rate 
which could conceiveably delay attainment of the (2) 
objectives. Thus it helps the management plan ~- .. 
the activities of its functional groups, in proper time 
sequence, for optimum results. The use of PERT/COST net-
works has also been. suggested, and may·be worthwhile to 
look into depending upon the si.tuation and size of the 
intended proje''ct. 
Early in the last decade when these techniques 
(CPM/CPA/PERT) were relatively new and product management 
area felt a lack of good new product planning techniques, 
it was only natural that .two were brought togather. How-
ever, in t·he recent yea.rs not i:nany new product management 
models incorporate their use. CPM/CPA/PERT techniques are 
. 
powerful and very useful tools of project management I but, 
- 18 -
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--- because of the inherent nature of new product management 
where there is always doubt about the worth of the project 
and question about its continuance, such techniques are 
not entirely suitable. 
- ,, 
Decision Mapping via-Optimum Go-No Networks• 
., 
Another approach to new product introduction is 
presented in a very elaborate network model DEMON (Deci-
. . 
sion Mapping via Optimum Go-No Network). !his paradigm was . 
developed by the advertising agency Batten, Barton, Dust-
rine & Osborn, Inc. (BBD&O). In this approach, the model 
is conceptualized as a network of data gathering studies 
I 
and decision alternatives. The nodes in such a network 
represent evaluation or decision states and the links rep-
resent the data gathering studies. At each node, the study 
resultsare evaluated and a decision is made, whether to 
'go national' (GO), 'abandon the product' (NO) or collect 
r 
some more information before making Go-No decision (ON). 
With reference to QO, the optimization is directed towards 
achieving the best possible GO state arrived at via market 
study and not merely achieving any GO state that will min-
imize the cost of the studies leading to this decision, or 
settle for some financial retu~n that might be less than (4) 
• maximum. 
., 
"' 
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• 
... 
·, 
• 
-- ---- .- .. · 
" 
.. 
.\ 
• ' • • • ,' • - ,- ? ' ' ' • ·~ 
.., • , • , 1 , , , 1 1 • ,. 1 • , , 1 , , , , , • , • 1 , • I• • • 
....... ~ 
According to the proponents, the technique used 
not only ~imilar to chance constrained programming, but 
also is a further devel·opment and .. extension of the same. 
Also, though DEMON is related 
theory, it differs from it in 
' to statistical decision (4) 
a number of ways: (1) the 
functional to be optimized, (2) the nature and domain of 
' optimization and (J) the type of probabilistic constraints 
specified. 
. Here in this approach, the management is supposed 
to have made its decision to-enter the network solution by 
DEMON after the completion of a pre-entry state in which 
• initial screening and preliminary e·con.omic analysis has 
been made. The proposed advertising, sales promotion, dis-
tribution and pricing plans are needed along with state-
ment regarding the top management policy constraints such 
as planning period, payout period, minimum acceptable pro-
.,fi t, marketing research budget ceili.ng, ·degree of confi-
dence needed, quality of project study, etc. One special 
feature here in DEMON is to treat 'payout•as a chance con-
straint rather than as objective furiction. This is done to 
give way to other objectives like maximizing the profits, 
etc. On the other hand, there are provisions for payout to 
.. 
• 
be treated as an objective, where the probability of achie-
ving the payout· is maximized or alternatively the payout 
period is minimized, subject to constraints on profit. 
- ·20 -
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Diverting our attention from constraints to objec-
• tive function, we find the objective of DEMON is,, to maxi-
~· ......... .!,~ 
.. 
mize expected maximum profit (the name given by the pro-
p onents is MEMP). In short the MEMP is supposed to have a (4) dual objective of choosing distribution ofs a best path 
through the network of study possibilities and a best de-
ployment of funds in terms of marketing plan. This dual 
objective assures that when a 'GO' decision is arrived at, 
the resulting decision sequence to follow is the best mar-
keting strategy in c·onformance with the marketing studies 
and not just·a minimum cost of study plan leading to this 
decision or a plan that will give some financial returns 
less than maximum. On the other hand, when 'NO' decision 
is reached the objective is to reach the decision at the 
lowest cost. Also provisions are available whereby it is 
possible to explore the new alternatives that become app-
I arent as the study proceeds, or to note the effect on 'GO' 
and 'NO' decision outcomes with changes in.initially stated 
company policy constraints. DEMON is a powerful technique 
f~r new product management and is currently being used by 
a number of BBD&O's client _companies • 
.. Specifications of Profits with Interaction under Trial and 
Error Responses 
One of the best models available today for aiding . 
t the new product planning and control proc·ess i.s called 
' 
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·-SPRINT ER (Specification of pro:ri·ts with interaction under· 
trial and error response). The model is similar to DEMON. 
in that it is also based· on network type approach, where 
information gathering studies are conducted and evaluation 
is made with recommendations at each step in the process, 
whether the product should be adopted (GO Decision), reje-
cted (NO Decision) or investigated further (ON.Decision). 
" The ·model also recommends the best price, advertising 
allocation and distribution le~el for the new product. 
The model becomes operational after an initial 
screening has been finished. The objective function, in 
· this model is to find the probability at the present stage 
of information gathering, that the new. product introduc-
tion would achieve the corporation:ts target rate of return. 
The speciality of the model is that it takes marketing mix 
and competitive response factor into account. The decision 
is made on the basis of incremental changes in the firmts 
profit and_ risk position. If because of the introduction 
of the new product, sales of the existing product lines 
-are lost, the lost profit is sustracted from the gross 
expected profits to be generated by the new product intro-
duction and the differential profit is used as a criterion (25) 
for judgement. The .solution to the problem is generated by 
a trial and error computer simuiation routine (rather than 
conventional mathamatical programmi~g techniques),· that 
- 22··-
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maximizes the·profit attributable to the new product .after 
. -giving full consideration to the effect of various levels· 
of price, advertising, distrbution, the competitive envir-1.J 
orunent ,surrounding the product, the constraints on the 
firm's operations and interdependencies between new pro-(26,28) 
duct and old products. 
The model has its limitations as it assumes that 
new product ideas come as individuals. The model can not 
choose the best new product idea from a group of new pro-
duct ideas, although it can supply differential profit and 
uncertainity information on each one of them separately. 
~ Yet -another limitation is that the method does not expli-
citly specify what further information gathering studies 
. 
should be conducted once a 'ON' decision has been reached. 
Instead it assumes that the best study is automatically 
. (25) 
conducted at each 'ON' decision. 
At present SPRINTER is available in four differ-
ent versions, riame ly SPRI'NTER MOD I , SPRINTER MOD !BS, 
SPRINTER MOD II, and SPRINTER.MOD III. The common aspects 
of all these versions have been described heretofore and 
their differences are discussed in the following. 
In mtist models the sales foreca.sts are generated. 
~y·combining test market share~ or sales with some subject-
ive ___ adjustments. In SPR1NTER (al.l versions) the forecasts 
- 23. -
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are generated by combining the trial rates with the number 
of potential tryers in the target group. The SPRINTER 'MOD I 
utilizes the adoption theory in the most elementary form 
by de~cribing the acceptence process of new product thro-
(28) 
ugh trial, repeats and loyalty. SPRINTER MOD I is a simple 
model, its data requirements are small, it takes less var-
iables into account and is the most inexpensive in this 
series of models, 
In the SPRINTER MOD IBS version (the behavioral 
science option of SPRINTER MOD I), the "trial rate is 
divided into processess of gaining awareness, developing 
. (28) 
intent to try (given awareness), and finding the product." 
As~~ca./iresult.~.,of these explicit and more· detailed definatios 
of process of acceptence, both the input data requirements 
and the capabilities of the model are enhanced, While the 
model is new capable of separately perceiving the effec;j; . 
of advertising budg~t, appeal and distribution; it requires 
extra input data regarding the percent of the people aware, 
the fraction of those aware who have a disposition to try 
the product, and the percent of product availability in 
each period. The computer time requirements are also in-
creased, and the model is costlier than SPRINTER MOD I. 
SPRINTER MOD II is a still more. sophistjcated 
model. It finds out the best marketing mix strat~gy for 
new ,product "by linking controllable v~riables of price 
- 24 -
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• , •4 "f,; •;-and adver·tising to the diffusion process," It also consi-, I 
ders the basic response model in more· detail by including 
awareness levels, in store brand choice, pheno-(26,~8) 
specific 
menon of forgetting, etc, This model also considers compet- · 
itive advertising effect and thereby can better comprehand · 
the interdependencies.of the market. 
SPRINTER MOD III is the last in the series, and 
the most powerful tool of decision making in new product 
planning and contra+ process, The model is supposed to 
fulfill following purposes,"(1) gaining meaningful beha-
vioral interpretations from test market data, (2) forecast-
·ing national sales levels before national introduction, 
',..,,_ __ ~P~-~ ....... , (J) recommending improved product strategies, (4) recomm-
ending a 'GO', .. 'NO' or 'ON' decision, and (5) identifying 
national introduction problems, recommending solutions to 
( 27) 
them, and generating revised s?1,les forecasts." In this 
model more variables are added, better process description 
is provided andrnew behavioral phenomenons are utilized.-
It takes into account and controls such variables as sam-
ples, cupons, point of purchase displays, shelf facings, 
middleman deals,-number of sales calls and price and adver-(28) · , 
tising. It also,~applies the behavioral theory of word of 
mouth communication, whereby the process is structured by 
determining how many users recommend the product and how 
many non-users requested the inform~tion. 
- 25 -
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SPRINTER MOD III is by far the best model avail-
able, in this family of new product planning and control 
models. It is extremely precise and incorporates high level 
of behavioral process details. Consequently, it requires a 
lot more-input information and is significantly more ex-
pensive than other models in the family. 
In the preceding discussi6ri, we have taken a gen-
eral overview of the corporate objectives, organization 
structure, business analysis methods and some advanced 
techniques for new product introduction. These are some 
of the important rudiments of new product development pro-
cedure. ·As far as, the procedure itself is concerned var-
ious general guidelines have been lai~ for new product I 
planning and control from time to time. These guidelines 
are usually focused so narrowly on a particular industry 
the author is referring to that they are of little value 
to anybody else outside that small industrial segement. 
In recent years, the most widely qouted and a typical 
framework for new product planning and control has been 
laid down by Booz, Allen and Hamilton, Inc., management 
consultants. According to this approach new product deve-
4 ( 14) lopment process should pass through following stages; 
"·Explorations The sea~eh.~ . .for product 
ideas to meet company objectives. 
Screenings A quick analysis to deter-
mine which ideas are pertinent and .... ,.,, .. _. .... , ,. 
merit more detailed study.· 
t\. - 26 -
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Business Analysiss The expansion of 
ideas through creative analysis, into 
a concrete business recommendation 
including product features and program 
for the prodlucto 
DevelopmentB Turning,the ideas on paper 
into a product in hand, demonstratable 
and producible. 
Testing, The commercial experiments 
necessary to verify earlier business jµdgements. 
Commercializations Launching the pro-
duct in full scale production and sale, 
committing the company's reputation 
and resources.") 
At this juncture, it must be realized, tha·t this particu-
lar guideline is a very generlized version and can be 
·applied to almost any industrial environment. However, 
various stages would vary in their relative importance 
, from industry to industry, and from product to product. 
. ... 
Pharmaceutical industry is an exceptionally good 
example of an industry that engages in new product devlop-_ 
ment with a great zeal. The relative importance this indus-
try places in the new product development function can be 
judged by the fact that research expenditure for new pro-
• 
duct development "ranges, according to (the pharmaceutical) 
company, from less than 5% to gr~ater than 15%, and aver-
ages around 10% of sales income throughout the wo-,rld. The 
( 3) 
average of all other industries is just over J%." The mag-
nitude of ,this activity Can be appreciated in light of the----
fact that the total expenditure for research and develop-
- 27 -
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ment of new drugs in this industry was 
over$ 600 million for the fiscal year 
estimated 
( 1 )- ) 
1971, 
to be 
Examining the new product development ~ithin the 
pharmaceutical industry i1lustrative of the Booz, Allen 
and Hamilton's approach, one realizes that certain stages 
of this approach are rendered quite unimportant or unnece-
ssary, while others are inflated in their significance. 
Exploration and screening are usually two very important 
stages, and are the recipiants of large time and efforts 
in new product planning and control, in most industries. 
Hereby, worthwhile ideas are conc~ived, collected and ass-
. 
esed. However, these stages are considerably reduced in 
their· significance, as far as the·pharmaceutical industry 
is concerned. This is so, as the problem areas (diseases 
that need cure) are fairly well known, and the methods 
for new product discovery are well identified. As a result, 
a well defined corporate policy takes over a good part of 
screening stage. In general, a new drug may be discovered 
' (j) . 
by any of the following four m~ans. First, through th-e-
use of fundamental research where the "disease process is 
studied in biological and biochemical terms with complete 
understanding of its aetiology and a replication of-the 
disease in an experimental animal," Second, through "syn-
thesis around known drugs or natural products. in the body, 
such a.s ·harmones or substances playing an important role 
in the ~isiology or pathalogicalmechanisms of the body." 
__ , 28 -
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Third, through· natural product screening. This is a: random 
screening of the products of fungi and plants. ·Many impor-
tant antibiotics have been discovered in this manner. 
Fourth, through "random screening of chemicals. This is a 
poor and inefficient way of looking for new drugs, since 
useful medicinal activity is not a common charachterstic 
of organic chemical substances. Injected in the above 
methods is the 'Empirical Accident•. Even, today it is a 
significant source of discovyery·." 
Business Analysis and Product Development are two 
stages of paramount importance, in new product introduc-
tion procedure within the pharmaceutical industry. Test 
Marketing is rendered quite useless, h~re. Usually, the 
purpose of the test marketing is to have some measure of 
customer whims and fancies (approval or disapproval), and 
the effects there of on sales volume of the intended pro-
duct, with the application of variable marketing mix. 
Within :phe pharmaceutical industry, the customer whims 
and fancies are of little importance, If a product can.be 
developed to cure a particular disease and does not create 
~jor toxicity problems (technical problems), the company 
can rest assured it would sell. Since the need of new 
drugs in particular disease areas is no secret and statis-
" 
tical data are freely available for the number of persons 
. ..,, -' 
afflicted by the disease every year, test marketing is of 
\~ 
little consequence. 
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• >r1 ...... '. '~ '' • Commercialization -of a·new product development, is 
relatively simpler in this industry. The advertising ca~-
paign is usually undertaken by ~·ending literature to 
major hospitals and individual physicians and specialists • 
• 
In light of the foregoing discussion,. it was felt 
that a study conducted within the pharmaceutical indust~; 
to determine the prevalent industrial practices-and to 
establish the special needs and problem areas within this 
industry, in so far as new product introduction is concer-
ned would serve to enhance the state of knowledge in this 
field. Such information and the conclusions drawn there 
· from would be of help and interest to the pharmaceutical 
manufacturers. The details of such a study are presented 
in the following chapters. 
:,.,~ ., 
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· CHAPTER II 
{, 
STATEMENT OF THE PR.OBLEM 
' 
Focusing ones sights on New Products Development 
one fi~s that despite the obvious importance of the new 
product development function in industry, there is a seem-
ing lack of a body of knowledge or theory to systematize 
the organization of efforts and commitment of resources 
for new products development. In recent years, a number 
of techniques have been developed for decision making·in 
new product development, hqwever these techniques only 
seem to deal with the problem on a piece meal basis. Also, 
to make matters worse even these techniques are not easily 
• 
acessible, as they are widely scattered in literature on 
Research and Devlopment, Marketing, Engineering, etc., 
and little attention has beeri directed to their organi-
zation. In light of the above, one of the objectives~ 
chosen for the study is to examine the techniques avail-
able, and to develop co~on charachterizations that may 
be generally applied. 
We have already shown in the preceding discus-
. sion, that the pharmaceutical industry in general devotes 
a substantial portion of their efforts and resources in 
- the development of the new drugs. On a percentage basis, 
the pharmaceutical companies divert a larger~portion of 
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of their sales proceeds in the new product development 
programs than almost any other segement of industry. In 
view of the above, it was decided to make an in depth, 
study of this industrial segement. The study is condu,cted 
to report the state of the arts of the new products 
development within the pharmaceutical industry. Specifi-
_cally, the study should determine the followings 
1. The importance.attached by the pharmaceutical 
manufaqturers to the organizational aspects of the new 
product development function, Here, we would .endeavour 
to determine the organizational structure most. commonly 
_ employed and the organizational structures prdne to suc-
cess or failure of the program. 
2. The impact of complex computer routines in 
successful i~troduction of new products within the pharm-
aceutical industry. Here, attention would be focused on 
various available models to determine the suitability 
or practicality of such models in new product development 
as it relates to the pharmaceutical industry,. and the 
extent of their exceptence and practical applications 
in this industrial segement. 
'" 
J. The identity of special problems and needs 
of the pharmaceutical-· industry, while engaging i_·n new 
product introduction. Here, attempts would be made to 
- .32 -
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establish the major reasons that account for the dis-
continuance of new product proposals. 
,. 
.• 
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CHAPTER II·I 
PROCEDURES 
Having decided that the subject of study would 
be the New Products Development procedures and practices 
within the Pharmaceutical Industry, efforts were directed. 
towards information gathering. Initially, a thorough and 
exhausti~e literature search was conducted in popular 
trade magzines, to make an appraisal 0 of the new product 
manage.ment techniques followed within industry in general. 
Later on, a close in depth search was focused-on trade 
\ 
~agzines related to the Pharmaceutical Industry alone. 
We have already reported the results of this literature 
' 
search in the preceeding discussion (C.hapter I). Some 
' 
personal interviews were arranged with New Product Deve-
lopment Managers of leading Eharmaceutical Companies. 
The resultant end Product of the literature search and .. 
the personal interviews was· a standard questionaire 
developed for the purpose of conducting the study. This 
questionaire was designed to generate information p~rtain-
ing to the pharmaceutical indtistry. Efforts were made 
(' 
to make the questionaire as brief as possible, and still ··· 
capable of gen_erating relevant and meaningful inform~~ 
tion. Following is a sampl~ copy of the standard question-
. ' 
aire, that was used for the purposes of the present study • .,1 
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SAMPLE QUESTIOAIRE 
t. Do you have a full time new product executive? 
D Yes D No 
2. Please check the kind of New Products Organization 
you have: 
D 
D 
A single brand manager for both existing and new products working within the marketing de·partmeni. 
A separate brand manager for new products working 
within the marketing department. 
D A new products committee forme~ from members of 
various departments meeting occasionally and 
reporting to the president. ' 
D A new products group working within Research and Development department. 
D. A new products group working separately and re-porting· to the president. Employing its own 
experts from various disciplines. 
D A 'Task Force' (or Venture Team) made· up of ex-perts, borrowed from various departments for the duration of the project • 
.D None of the above. Please comment, if you feel 
that the above classification does not describe your situation. 
a. Do you make Business (or Economic) Analysis for new product proposals, before engaging in its development? 
.D Yes D No 
4. If the Business (or Economic) Analysis is made, which 
model is us·ed: 
L7 Break Even Model 
.D Decision Tree Type Approach 
\ 
Continued ••.••••• 
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D· ·-·-----: Cash _Flow Model (Utilizing Present Value Method 
or Rate of Return on Investment Approach) 
D None of the above. Please comment, if you feel 
that the above classification does not include 
your modelo 
_5. Do you have a formalized decision making process. If so, 
please check: .. 
D 
J 
D 
D 
D 
D 
Use of Expected Value Principle incorporating 
one of the above mentioned basic models. Cal-
culation0of one or more of the following for 
decision making: Expected Profit, Expected Pay-
off Period, Expected Profit to Investment 
Ratio, etc. 
I 
Use of Marketing Mix Model inco.rporating one of 
the above mentioned basic models. The decision 
is reached by taking into account various mar-
keting strategieso The use of uncertaininty data 
partially or wholly. 
Use of computer simulation (Monte Carlo or other-
wise) to incorporate uncertainty data in decision 
making. 
Use of specialized computer routines, such as 
SPRINTER,-DEMON, etc. 
None of the above. Please illustrate. 
.-
6. Within your company, what percentage of total sales 
could be a~counted towards products introduced within , · 
~ past five yearss 
Your Estimate 
• 
7. Within your company what factors contributed most in 
discontinuance· of new product proposals. Please award' 
a score on the' following scale. 
Continued ••••.••• 
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j Very Important 4. Important 
-
·1 . Significantly Important 
1 .Not At All Important 
2 Not Quite Important 
-
(I) 
{II) 
(III) 
( IV·) 
(V) 
(VI) 
(VII) 
Desiin Incompatible with Consumer needs 
and/or values 
Need for Earlier Business (or Economic) 
Analysis 
Need for Earlier Market Information 
Drop in Company Priority or Interests 
in the Product 
Technical Difficulties during Development 
Lo~ Projected Volume 
High Unit Cost 
(VIII) Late Introduction of the product to the 
markett 
(IX) Any factor you might feel important, but 
not listed here. Please elaborate. 
*General Comments. 
. 
..... . -.... ·. ~ ____ 1 ' 
-~ 
Thanksl 
• 
".;..,, ... · _._,.,. 
• 
....; 
". 
• 
.- . ' 
This questionaire was later used in a survey 
~onducted by mail. For the purposes of this,survey the 
Pharmaceutical Manufacturers Association provided a list-
ing of all the national pharmaceutical companies, and 
the names of their New Product Managers. We are very much 
obliged to the Pharmaceutical Manufacturers Association 
. 
for providing us with this pertinent information. By 
helping us with a comprehensive upto-date list, the repu-
ted association not only saved us much time and effort, 
it also ensured us of a complete coverage in this indus-
trial segement. In this survey, all 103 national pharma-
ceutical companies were requested to supply the informa-
tion regarding the practices and procedures followed by 
them, when engaging in new product development. The sur-
vey resulted in replies from 40 of these companies. At 
• 
this juncture, we must again thank these companies for 
taking an interest and providing us with such an over-
\ 
whelming response to our survey. Needless to sa~, that 
.anybody with an iota of experience in conducting survey 
realizes that a 38% (approx.) response to a survey by~ 
mail is unusually high. Five companies among those reply-
ing failed to fill out the questionaire for a variety of 
reasons. Though no pertinent useful information resulted 
from these five replies, the courtesy of reply is very 
. . 
much appreciated. In,the end, the information received 
. 
. 
from 39 companies ( 4 companies that were personally in-( 
- J8 -
<!, 
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,. 
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,' ~. 
terviewed and 35 companies that supplied the· requested 
information) was evaluated for re.sults presented in the 
following chapter~. 
In the questionaire presented here, the first 
portion containing the first two questions deals with the 
organizational aspects of the· problem. The first question 
provides a measure of the importance, the company places 
in the new product planning and control function. The 
second question seeks to find the kind of organizational 
structure that is more commonly used than others. Some 
latent characterstics of the new product development fun-
·'·---
ction within the confines of the pharmaceutical industry 
• 
may have bearings on this answer. It should be possible 
to gain an insight of these charachterstics through the 
answers obtained, Also, the second question in conjuction 
" 
with sixth question could possibly provide a measure of 
the organizational success in introducing new products, 
whereby it may be possible to identify success or failure 
prone organizational structures. 
The second portion of the questionaire containing 
questions three through five, addresses itself to the 
business management aspects of the problem. This portion 
of the study should generate data pertaining to the extent 
of the application of yarious business management ·techni--
ques for new product dev'elt>pment within the pharmaceutical 
- 39 -
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indu·stry. The suitability or practicality of complex com-
. -· . puter routines for the successful introduction of new 
. drugs and the extent of their application is a measure 
of their· impact within the industry. Further, the extent 
of the use of ~hese specialized complex computer simula-
tion routines {such as DEMON, SPRINTER, etc.) reflects 
r 
an appraisal of the appropriatene~s and possible effective 
applications j_n the pharmaceutical industry, by the people 
~esponsible for the new product development fuunct.ion 
within this indiistrial segement. In this context, during 
the course of our interviews with the new product managers 
of the four leading pharmaceutical companies, it was noted 
that although all four of these companies were aware of 
the availability of such models, only one company utilized 
·' 
them. 
Finally, the seventh question is designed to pro-
vide information relating to the nature of problems most 
commonly encountered in introducing·new drugs within the 
pharmaceutical industry. This question was included to 
allow responsible new products managers to make a value 
judgement, and to express their opinions of problems'in 
and nature of new product development in this industrial 
I 
' . 
segement. This. question not only allows the new products 
managers to excercise their own subjective judegement, 
1 l'but also relieves them from approving_ narrow .or restric-
- 40 -
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ti v e viewpoints. The results may very well provide new 
insights and develop thoughts that might have escaped 
our attention. The information generated here would be 
useful in avoiding the common pitfalls and identifying 
the problem areas that need special attention of both 
the model makers and decision makers. 
I, 
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.. 
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-.~ CHAPTER IV 
RESULTS 
\ In the following, we present the restilts of the 
·c~rrent study, 'New Product Development - A Study of Man-
agement Structures and Economic Evaluation Practices and 
Procedures in Pharmaceutical Industry'. As mentioned ear-
lier, the study·was conducted within 103 national pharma-
ceutical companies. The results presented here, have been 
compiJ_ed from the answers received .. (at random) from 39 ... ;of 
these 103 national pharmaceutical companies. Although the 
results presented here represent only J8% (approx.) of the 
national pharmaceutical companies by actual count, we sus-
pect from the answers received that they in fact represent 
a much larger percentage of sales dollar volume of the 
pharmaceutical industry. This is only a subjective view-
point, based upon the feeling that the larger corporations 
··· took a greater interest in the survey and provided answers 
about their new product development procedures. It is to 
...... 
t9 
be realized here that information on the sales volume con-
tributed by p~esgription pharmaceutical products to these· 
large corporations is hard to get. In view of the above 
we believe that these results are representative of t·he 
pharmac~utical industry in general,· The results have been 
broken into-two sections, namely 'Organizational Aspects• 
and ··Business Management Aspects' • 
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Organizational Aspects• 
1. Among the companies that provided the reque-
sted information, it was found that approximately three 
out of every five of these pharmaceutical companies have 
at least one.full time new product executive, and two 
do·not. 
S.No. DESCRIPTION 
1 Companies Having At ·Least One 
Full Time New Product Executive 
.2 Companies Having No Full Time 
New Product Executive 
YES 
61.6% 
NO 
)8.4% 
/\ 
QTY. 
24 
15 
\ 
PERCENT 
61. 6 
J8.4 
-~ --. 
•.· i. 
( 
Companies Having at Least One Full Time 
New Product Executive 
~. 4J -
I• 
. i~: 
; .. l .. 
),·· -/--..._ 
e , 
. ~ .. 
' 2·. Further, it was noticed that among the com-
panies that have at least one full time new product exec-
utive, the various organizational structures have the 
following distribution. 
:t... ....... , .•. 
Cl) 
a, 
•rl 
s:: 
m 
A 
e 
0 
0 
~ 
0 
~ 
·} 
,· 
,i 
.. 
I 
~; 
• 
10 
. J.. 
,; 
r 
. . :, . 
; 
4 4 
~ 
1 1 
H 
H H >· 
H H H H > 
Cl) Q) Q) Q) (IJ 
~ ~ ' p.. A A 
» ~ ~ ~ >, 8 E-t 8 E-t 8 
Type of Organization 
• 
Organizational Structure Distribution 
for Companies-with at Least One Full 
Time New Product Executive 
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TYPE OF 
ORGANIZATION 
STRUCTURE 
.·.!:1. 
·1.,,. 
I 
II 
III 
IV 
v. 
VI 
.. 
DESCRIPTION 
Single Brand Manager 
Separate Brand Manager 
New Product Committee 
, .. 
New Product Group in R & D 
Separate New Product Group 
Task Force . 
NUMBER 
OF 
COMPANIES 
1 
4 
10 
1 
4 
4 
Also, it was noticed that among the companies 
that do not have a full time new product executive, the 
various organizational structures have the following 
distribution. 
TYPE OF 
ORGANIZATION 
STRUCTURE 
.,. 
I 
II 
III 
IV 
V 
VI 
·,.., 
DESCRIPTION 
Single Brand Manager 
Separate Brand Manager 
New Product Committee 
New Product Group in R & D 
Separate New Product Group 
Task Force 
. , 
:. ··_.:. 
--.. ·.I' 
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NUMBER. 
OF 
COMPANIES 
2 
0 
6 
4 
1· 
2 
• ! ... , .... 
. ' i 
, m 
(I) 
•r-t 
,. 5::: 
m 
A 
s 
0 
(.) 
G-i 
0 
~ 
·' 
.. 
6 ·' 
' 
4 
" 
.. 
2 
I 1 
0 
H 
H H > H H H H > 
(l) Q) (l) Cl) Q) 
Pt ~ A A Pt ~ ... ~ ~ >-> » 8 E-f E-t E-f E-t 
Type of Organization-·--~•-
,,, . ... 
Organizational Structure Distribution 
. for Companies with No Full Time 
·New Product Executive 
. 
! 
' : 
.. 
: 
2 
, 
H 
> 
Q) 
.A 
~ 
8 
' On a overall basis, following orgapizatiorial 
structure d,i.stribution was observed. 
·'1~ .• 
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Type of Organization I .. 
Organizational Structure Distribution. 
fer Pharmaceutical Companies 
-· Engaging in_ New Product· Development 
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TYPE OF 
· ORGANIZATION 
STRUCTURE 
I 
·· II 
III 
IV 
V 
VI 
• I 
DESCRIPTION 
Single Brand Manager 
Separate B~and Manager 
New Product Committee 
New Product Group in R & D 
Separate New Product G~oup~ 
Task Force 
NUMBER 
OF 
COMPANIES 
J 
4 
16 
} 
5 
5 
6 
For the companies with at least one full time 
.. 
new product executive, the different organizational struc- · 
tures generated the following percentages of sales in 
marketable new products, over a period of past five 
years. 
TYPE OF 
ORGANIZATION 
STRUCTURE 
I 
II 
III 
. :-· .. 
IV 
v. 
. ' VI 
PERCENTAGE OF SALES 
GENERATED BY NEW PRODUCTS 
INTRODUCED IN PAST FIVE YEARS 
-. 
50 , 2 5 , 15 , 9 • 
J-. 7 , 15 , - , 2 0 , 2 0 , 2 0 , 1 0 , 40 , 15 , 27 • 
10. l ' ' 
' 
,__ 2 5 , - , 2 5 , 3 O • 
.01, o, 27, 20. 
·--Also, for compani~s with no full time new product 
executive, the different organizational structures gener~ 
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ated following percentag.e{s ot sales in marketable new 
products, over a pe.riod of past five years. 
TYPE OF 
ORGANIZATION 
STRUCTURE 
I 
II 
\ 
I 
III 
IV 
V 
VI 
PERCENTAGE OF SALES 
GENERATED BY NEW PRODUCTS 
INTRODUCED IN PAST FIVE YEARS 
10. 18. 
• 
20, 16, 5, 12, 50, 20. 
,. I' 
10, 23, 2, 22 •. 
15. 
O, 48. ·.r· 
Business Management Aspectss 
... , .... 1~·-
As far as the use of business management tech-
niques are concerned, the study revealed that 37 out of 
39 Pharmaceutical Companies (94.87%) providing the requ·e-
sted information make some sort of a business analysis 
prior to engaging in New Product Development activity. 
Only 2 out these 39 companies did not engage in business 
analysis at all, a mere 5.13% of this industrial segement. 
Further, it was noticed·that among the Pharmaceutical Com-
panies that made .such such Business Analyses (37 companies) 
16.21% of the companies (6 companies) made· only Break Even 
Analysis, 13,52% of the companies (5 companies) utilized 
a Decision Tree Type Approach, 56.76% of the 9ompanies 
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Cash 
Flow 
Model 
,•;'}·. 
\' . 
56.76% 
·' 
l .· ·;_ 
All the 
.Three 
Models 
8.11% 
13.52% 
16.21% 
Decision 
.Tree 
Type 
Approach 
Break 
Even 
Model 
Br~ak Even Model 
& Cash Flow Model 
Percentage _of Companies Using Different Models 
for Bus-iness Analysis of New Product Development 
Proposals within Pharmaceutical Industry 
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(21 companies) made only Cash Flow calculations, 5.40% 
of the companies (2 companies) made multiple analyses .. 
where .both Break Even Model and Cash· Flow Models were 
used,· and finally 8·.11% -of the companies (3 companie,s) 
made a thorough analyses that included ~11 the three of 
the above mentioned models. 
' While using the above mentioned business mana-
. gement techniques·, 67. 57% of the· companies ( 25 out of 
37 companies) that engaged in bu'siness analysis prior 
to engaging in new product development activity, used 
simple expected value principle in their calculations, 
• 
An additional 16.21% of the· companies (6 companies) par-
tially utilized the uncertainty data through the use of 
simple marketing mix models. Of the remaining 16.22% 
; ~-
of the companies (6 companies) that utilized more advanced 
computer simulation routines for their business analysis, 
only half the companies were found to be using well known 
computer routines such as 'SPRINTER', 'DEMON', etc. 
The final portion of the study was directed to-
wards the determination of major reasons contributing to 
the discontinuanc·e of New Product Proposals in Pharmace-
·----
u tic al Industry. Presen~ study revealed that three majo~·--
reasons for the discontinuance of New Product Proposals 
area 
- 51 -
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(i) 'Technic~l Difficulties' encountered during 
Product Development phase. (Long arduous search, toxicity 
problems, etc.) 
(ii) 'Low Projected Volume'. 
(iii) 'Product Design incompatible with consumer 
needs/phisiology•. 
Three other important factors often contributing 
· ~ to the discontinuance of the new product proposals are 
.. ,};). 
.:. 
. 
listed below. ·These reasons although rated high by the .' : 
pharmaceutical companies, were not considered quite as 
important as the ones mentioned above. 
(iv) 'High Unit Cost'. 
(v) 'Drop in company priority or interest in the 
product'. 
(vi) 'Late introduction of the product to the 
market'. 
The reasons considered least important for the 
discontinuance of the new product proposals area 
(vii) 'Need for earlier market infrirmation'. 
(viii) 'Need for earlier Business Analysis'. 
Finarlly, the. last but pro-babily the most import-
ant factor resulting in_ the discontinuance of ~ew: p~odurcftr 
proposals .. was found to be the time, expense and efforts 
" 
0 
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involved in getting a FDA's (Federal Drug Adminstration's) 
approval for the drugs, ·prior to the final introduction 
of the new drug into the market. By far, this remains a 
major reason of concern to the pharmaceutical companies, 
as revealed in the present study. In general it takes a 
period of 5 - 7 years for the development of a new drug. 
An~additiona1· period of 1 - J years may be required in 
obtaining t~e necessary FDA approval. In effect, after 
solving all· the technical problems and spending huge sums 
of money in the development of these drugs under the con-
ditions of severe competition and dangers. of industrial 
piracy; the companies find themselves totally dependent 
upon FDA regulations that make the difference between a 
successful and an unsuccessful product. Further, due to 
the large amounts of time needed for product development 
and in obtaining the FDA's approval. the pharmaceutical 
companies are subjected to additional risks arising out 
of possible change in FDA regulations during the incuba-
tion period • 
.• 
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CHAPTER. V 
CONCLUSIONS 
·;::_ 
In view of the explbratory nature· of .our study 
and the relative non-quantitative form of the results, 
the conclusions drawn in the following tend to be discus-
sion oriented and somewhat subjective .rather than in pre~ 
cise matham.etical terms. As the reader would realize, the 
objective of the current study was to take a broad over-
' 
. . " 1' 1, 
' 
' 
' 
view of the nature of and problems in new product develop-'. 
' 
I 
- I 
, I 
ment within the pharmaceutical industry; and not to com~ 
\ 
I 
\ 
up with some mathamatically·rigorous app~baches or resutts. 
. • • I 
The whole new product development field tends to be very 
amo~phous or subjective, and little that can be generally 
applied has been developed. As mentioned earlier, this 
is because what is involved here is - creative, success-
ful and meaningful output under the conditions of finan-
cial risk, need for maintaining the company's position, 
meeting the requirements of goverment regulatory bodies, 
and finally the time pressures because of s~vere compe-
-
tition~ In this study, we have taken initial steps-towards 
sizing·up the situation, whereby certain ba~ic educated -
opinioris can be formed so that future efforts may be dire-
cted in a more.meaningful manner. From the results -present-
ed in the p1'evious·cliapter, we conclude the following: 
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Organizational Aspect"s a 
1. The development of new products is of great 
·interest to the Pharmaceutical Industry in general. 
•i' 
Roughly three out of every five companies in this·· indus-
) 
trial segement were reported to have at least one full 
time new product executive. 
2. The results further indicate that the most 
commonly utilized organizational structure withi~ the 
Pharmaceutical Industry seems to.be the new products 
" 
committee formed from members of various departments meet-
ing occasionally and reporting to the president. While 
the new product committees are discouraged in mo$t indus-
trial segements, surprisingly enough this type of organi-
zational structure was found to be of overwhelming popu-
larity here, both in the companies having at least one 
full time executive and the companies having no full time 
executive. 
) 
J. In.our study all the national Eharmaceutical 
Companies were contacted and a questionaire was mailed 
to each one of them. Although a unusually.high percentage 
-
of these companies responded to our request of. inf'orma-
tion, we found that in certain categories the absolute 
-
number of re_sponses receieved were in fact small. For 
example, the data on the percentage of sales generated 
-----
-- -----
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by the new products introduced in past ·rive years, by the 
individual companies were so small that it was impossible 
.. 
to carry out any kind of a statistical analysis. Hence, 
no formal correlation could b·e found between the organi-
zation structure and the the percentage of sales accounted 
towards new products introduced in past five years. The 
results in their present form remain inconclusive • 
• ;.... l,,. 
Business Management Aspects: 
1. The use of complex computer simulation routines 
was :found to be minimal. A mere,r 16. 22% of the companies 
-
in this i~dustrial segement used computer:_-simulation for 
' 
new products development in any form. The above could be· 
attributed to reasons such as.unawareness of the presence 
of these models, models incompatible with the needs of 
the Pharmaceutical Industry, prohibitive costs, etc. In 
this context, during the course pf our interviews at four 
le~ding Pharmaceutical Companies, we found that despite 
the fact that all of these companies knew about the pre-
. sence of such models, only one of these used .computer 
simulation in any form for new product development. We. 
realize that this sample is too~$mall_to found anj-con-
--
c re t e conclusions on its basis, all the same we present -
- this information to the readers for-whatever it is worth. 
Further, regarding the cost of these models, we feel that 
it is highly unlikely that the Pharmaceutical Industry 
- 56 -· 
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" (that_spends such a large portion of their sales towards 
0 
new products development) would ~ind these mode~s too 
expensive to use; should "it be proven that they can make 
some meaningful contribution towards the succes~ful intro~ 
. duction of new products, within the framewo~k of this 
industry. Most of these computer simulation models become 
effective 'slightly before the commercialization .,~tage, 
when the product is well in hand. These models usually 
devise· optimization of marketing strategies through the 
predictions of market share, interaction of ne~ product. 
sales with existing product lines, promo-t·io·nal res:pon·s.e 
_---:;-- --- --
of the consumer, etc. In this context, in response to 
seventh question of the questionaire mailed for the survey, 
the Pharmaceutical Manufacturers unanimously agreed that 
' the market information is of least significance in intro-
ducing new prescription pharmaceutical drugs. This may 
be because of the fact that in the field of prescription 
pharmaceuticals the statistics on people afflicted every 
year by various disease is quite freely available. In 
' 
most cases, the Pharmaceutical ,Companies know that if a 
good drug is disc.overed it would sell. Also, it is a well 
known fact that the elasticity of prescription pharmace-
uticals demand with price is quite minimal. This rnay_be 
attributed to the basic self preservation instincts. In 
" 
view of the above, it is ~ur contention that while these' 
algorithums may be good management tools for successf~l . 
- . 5t. -
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introduction of new ,products in other consumer ori.ented 
' 
industries1 they do not apply to the Ph~rmaceutical Indus-
try, because of the basic nature of ±he new products in-
troduction process in this industrial segement. 
2. Our study revealed that the three most common 
reasons contributing to the discontinuanc~ of new product 
,, 
proposals in the Pharmaceutical Industry are basic 'Tech-
nical Difficulties• during product development phase, 
'Low Projected Volume' and ·, Product Design incornpa tible 
_.,. with Consumer needs/phisiology'. The next three factors 
in the order of their importance were 'High Unit Cost', 
'Drop in Company ~riority or Interest in the Product', 
' -
and 'Late Introduction of the Product to the Market'. 
Finally the least important being the 'Need for Earlier 
Market Information' and 'Need for Earlier Business Ana~ 
lysis'. Most of.these are self explanatory and need no 
I 
clarification. The reader will notice that 'Low Projected 
Volume' was considered of higher importance in disconti-
nuance of new product proposals, than 'High Unit Cost'. 
This can again be explained by the relative inelasticity 
of demand with price. 
r 
Some of the other reasons attributed to the dis-
continuance of new product proposals were 'DifficuJty 
and Expenses involved in obtaining approval of FDA• , 'Change 
in FDA regulatory status during development period', 
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'Compound failure in Clinical Testing to meet Ob.iecti-ves•, 
etc. In the survey·; we found that the first two of these 
reasons were much emphasized. It is our opinion that while 
the Pharmaceutical Industry's concern of difficulties and 
expenses involved.in _obtaining approval of .FDA'is to be 
appreciated, an obsession of these is to be avoided. 
Inasmuch as these are good reasons of concern they also 
provide a legal protection to the industry from non..:.appre-
ciative consumers. • 
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